journal
MENU ▼
Read by QxMD icon Read
search

Immunotherapy

journal
https://www.readbyqxmd.com/read/28399693/pembrolizumab-in-recurrent-advanced-cervical-squamous-carcinoma
#1
Pablo Martínez, Josep María Del Campo
No definitive cure is known for recurrent, persistent or metastatic cervical carcinoma. Chemotherapy remains the standard of care, although available options are scarce and do not provide satisfactory results. Immune checkpoint inhibitors have shown a strong and prolonged response in several types of cancer, although only in a subset of patients. Defining the profile of the patients likely to benefit from such treatment is a subject of active research. Here, we present a case of a heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix who had exhausted all available treatment options and showed a striking response to the immune checkpoint inhibitor pembrolizumab...
April 12, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28351180/plac1-immunization-does-not-induce-infertility-in-mice
#2
Arcangelo Liso, Francesca Massenzio, Fabrizio Stracci
AIM: Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could possibly be part of future immunotherapeutic strategies. We investigated whether vaccination against PLAC1 could induce infertility. MATERIALS & METHODS: We inoculated female mice with PLAC1 peptides, put them in mating, measured antibody response (ELISA assay) and checked, in immunohistochemistry, binding of the induced antibodies to the native antigen...
March 29, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28357918/systemic-therapy-for-previously-untreated-advanced-braf-mutated-melanoma-navigating-a-shifting-landscape
#3
Oren Levine, Tahira Devji, Feng Xie
No abstract text is available yet for this article.
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28357917/the-ongoing-evolution-of-antibody-based-treatments-for-ebola-virus-infection
#4
Emelissa J Mendoza, Trina Racine, Gary P Kobinger
The 2014-2016 Ebola virus outbreak in West Africa was the deadliest in history, prompting the evaluation of various drug candidates, including antibody-based therapeutics for the treatment of Ebola hemorrhagic fever (EHF). Prior to 2014, only convalescent blood products from EHF survivors had been administered to newly infected individuals as a form of treatment. However, during the recent outbreak, monoclonal antibody cocktails such as ZMapp, ZMAb and MB-003 were either tested in a human clinical safety and efficacy trial or provided to some based on compassionate grounds...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28357916/chimeric-antigen-receptor-engineered-stem-cells-a-novel-hiv-therapy
#5
Anjie Zhen, Mayra A Carrillo, Scott G Kitchen
Despite the success of combination antiretroviral therapy (cART) for suppressing HIV and improving patients' quality of life, HIV persists in cART-treated patients and remains an incurable disease. Financial burdens and health consequences of lifelong cART treatment call for novel HIV therapies that result in a permanent cure. Cellular immunity is central in controlling HIV replication. However, HIV adopts numerous strategies to evade immune surveillance. Engineered immunity via genetic manipulation could offer a functional cure by generating cells that have enhanced antiviral activity and are resistant to HIV infection...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28357915/early-relapse-in-a-case-of-primary-bone-marrow-diffuse-large-b-cell-lymphoma-treated-with-rituximab-chop
#6
Wanning Wang, Guang-Yu Zhou, Wenlong Zhang
As an uncommon disease, primary bone marrow diffuse large B-cell lymphoma (PBM DLBCL) is rarely reported in recent years. In this paper, we discuss a case of a 58-year-old man who presented with fever and fatigue, and was diagnosed with PBM DLBCL. Although the initial diagnosis reflected a positive expression of CD20 by lymphoma cells, the course of disease appeared as a rapid remission but a quick recurrence, after eight cycles of rituximab-based immunochemotherapy (R-CHOP). With the positive expression of CD20 in recurrent lesions, he received another four cycles of rituximab-based immunochemotherapy (R-GDP)...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28357914/short-review-of-potential-synergies-of-immune-checkpoint-inhibition-and-radiotherapy-with-a-focus-on-hodgkin-lymphoma-radio-immunotherapy-opens-new-doors
#7
Christian Baues, Maike Trommer-Nestler, Karolina Jablonska, Paul J Bröckelmann, Max Schlaak, Michael von Bergwelt-Baildon, Andreas Engert, Robert Semrau, Simone Marnitz, Sebastian Theurich
Radiotherapy is an established local treatment in patients with various malignancies. Systemic responses following local irradiation have been described as abscopal effects. Modern cancer immunotherapy with immune checkpoint inhibitors has shown impressive response rates and prolongation of survival even in heavily pretreated patients with advanced solid malignancies and lymphomas. Radiotherapy has been shown to modulate immune response, and its application in the context of immune checkpoint inhibition has recently evolved into an active field of research...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28357913/current-update-of-adoptive-immunotherapy-using-cytokine-induced-killer-cells-to-eliminate-malignant-gliomas
#8
Je Il Ryu, Myung Hoon Han, Jin Hwan Cheong, Jae Min Kim, Choong Hyun Kim
The therapeutic outcome for those with malignant glioma is poor, even though diverse therapeutic modalities have been developed. Immunotherapy has emerged as a therapeutic approach for malignant gliomas, making it possible to selectively treat tumors while sparing normal tissue. Here, we review clinical trials of adoptive immunotherapy approaches for malignant gliomas. We also describe a clinical trial that examined the efficacy and safety of autologous cytokine-induced killer (CIK) cells along with concomitant chemoradiotherapy for newly diagnosed glioblastoma...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28357912/bioinformatic-prediction-and-experimental-validation-of-a-pe38-based-recombinant-immunotoxin-targeting-the-fn14-receptor-in-cancer-cells
#9
Maryam Keshtvarz, Jafar Salimian, Mehdi Yaseri, Seyedeh Zahra Bathaie, Ehsan Rezaie, Amir Aliramezani, Zahra Norouzbabaei, Jafar Amani, Masoumeh Douraghi
AIM: AFn14R can serve as an ideal target for cancer immunotherapy. Here, a combined bioinformatic and experimental approach was applied to characterize an immunotoxin consisting of single-chain variable fragment antibody that targets Fn14 and a toxin fragment (PE38). METHODS & RESULTS: Flow cytometry results showed that the rate of PE38-P4A8 binding to Fn14 was approximately 60 and 40% in HT-29 and A549 cells, respectively. Moreover, 1 ng/µl of immunotoxin was able to lyse approximately 53 and 41% of HT-29 and A549, respectively...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28357911/advances-in-urothelial-bladder-cancer-immunotherapy-dawn-of-a-new-age-of-treatment
#10
Fouad Aoun, Elie El Rassy, Tarek Assi, Simone Albisinni, Joseph Katan
Urothelial bladder cancer displays a high number of somatic mutations that render these tumors more responsive to immunotherapy. Several immunotherapeutic agents were examined in patients with advanced stage urothelial bladder cancer and recently atezolizumab - an (PDL-1) immune checkpoint inhibitor antibody - was approved for the treatment of patients with metastatic disease progressing after platinum combination therapy. Despite the great success, there are still some unanswered questions and ongoing trials that are in progress to define the role of combination therapy and sequencing strategies...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28303770/corrigendum
#11
(no author information available yet)
No abstract text is available yet for this article.
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28303769/neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities
#12
Cory A Brennick, Mariam M George, William L Corwin, Pramod K Srivastava, Hakimeh Ebrahimi-Nik
Over the last half century, it has become well established that cancers can elicit a host immune response that can target them with high specificity. Only within the last decade, with the advances in high-throughput gene sequencing and bioinformatics approaches, are we now on the forefront of harnessing the host's immune system to treat cancer. Recently, some strides have been taken toward understanding effective tumor-specific MHC I restricted epitopes or neoepitopes. However, many fundamental questions still remain to be addressed before this therapy can live up to its full clinical potential...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28303768/diffuse-edema-suggestive-of-cytokine-release-syndrome-in-a-metastatic-lung-carcinoma-patient-treated-with-pembrolizumab
#13
Elie El Rassy, Tarek Assi, Jamale Rizkallah, Joseph Kattan
Immune checkpoint inhibitors (ICIs) are actually being indicated more commonly in the management of chemoresistant cancer patients in view of their favorable toxicity profile in comparison to cytotoxic chemotherapy. In this paper, we report, to our knowledge, the first case suggestive of cytokine release syndrome secondary to pembrolizumab in a patient with metastatic lung squamous cell carcinoma. In view of the quick approvals of ICI and the absence of sufficient knowledge of the corresponding toxicity profile, the occurrence of any clinical or biological sign or symptom in patients receiving ICI requires further investigation...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28303767/immunomonitoring-reveals-interruption-of-anergy-after-vaccination-in-a-case-of-type-2-papillary-renal-cell-carcinoma
#14
Maria A Clavijo-Salomon, Patricia C Bergami-Santos, José Alexandre M Barbuto
With the enormous and growing interest in the clinical application of immunotherapy, we are currently facing the need to accurately monitor the immune function of cancer patients. Here, we describe changes in the immune status of a patient with metastatic type-2-papillary renal cell carcinoma, before and after surgery and subsequent immunotherapy with a dendritic cell-tumor cell hybrid vaccine. Through the accurate assessment of monocyte-derived dendritic cells (Mo-DCs) function, we show that Mo-DCs were freed from tumor-induced maturation blockage by tumor resection surgery, while Mo-DCs-tumor induced suppression and anergy were only interrupted by the vaccination treatment...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28303766/prospects-of-combining-adoptive-cell-immunotherapy-with-bortezomib
#15
Samuel T Pellom, Ashutosh Singhal, Anil Shanker
No abstract text is available yet for this article.
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28303765/the-significance-of-the-levels-of-il-4-il-31-and-tlsp-in-patients-with-asthma-and-or-rhinitis
#16
Ruonan Chai, Beixing Liu, Feifei Qi
AIM: To investigate the clinical significance of the levels of IL-4, IL-33 and thymic stromal lymphopoietin (TLSP) in patients with asthma and/or rhinitis, then do the simple verification in animals. METHODS: Levels of IL-4 IL-31, IL-33 and TLSP were detected by ELISA and real-time PCR in 64 asthma patients (sIgE[+]: 32 cases, sIgE[-]: 32 cases), 64 rhinitis patients (sIgE[+]: 32 cases, sIgE[-]: 32 cases), 64 asthma complicated with allergic rhinitis patients (sIgE[+]: 32 cases, sIgE[-]: 32 cases) and 32 healthy controls...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28303764/recent-progress-in-gm-csf-based-cancer-immunotherapy
#17
Wan-Lun Yan, Kuan-Yin Shen, Chun-Yuan Tien, Yu-An Chen, Shih-Jen Liu
Cancer immunotherapy is a growing field. GM-CSF, a potent cytokine promoting the differentiation of myeloid cells, can also be used as an immunostimulatory adjuvant to elicit antitumor immunity. Additionally, GM-CSF is essential for the differentiation of dendritic cells, which are responsible for processing and presenting tumor antigens for the priming of antitumor cytotoxic T lymphocytes. Some strategies have been developed for GM-CSF-based cancer immunotherapy in clinical practice: GM-CSF monotherapy, GM-CSF-secreting cancer cell vaccines, GM-CSF-fused tumor-associated antigen protein-based vaccines, GM-CSF-based DNA vaccines and GM-CSF combination therapy...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28303763/case-report-of-nivolumab-related-pneumonitis
#18
Kohei Tada, Yasuyuki Kurihara, Tomohiro Myojo, Fumitsugu Kojima, Yuya Ishikawa, Nobuyuki Yoshiyasu, Masaya Morimoto, Reiko Ito, Ryosuke Koyamada, Takuya Yamashita, Toru Bando, Shinichiro Mori, Yuji Heike
We report a case with suggestive antiprogrammed death-1 inhibitor-related pneumonitis in an endometrial cancer patient. This case presented with fever and cough after three dosages of nivolumab. Computed tomography initially showed centrilobular nodularities in a unilateral lung, which was compatible with aspiration pneumonia. However, diffuse ground-glass opacities (GGO) rapidly developed in the unilateral lung over 4 days despite the use of broad-spectrum antibiotics. Development of GGO was considered to be related to a nivolumab-mediated immune reaction...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28303762/tlr9-based-immunotherapy-for-the-treatment-of-allergic-diseases
#19
Shokrollah Farrokhi, Narjes Abbasirad, Ali Movahed, Hossein Ali Khazaei, Masoud Pishjoo, Nima Rezaei
Toll-like receptors (TLRs), a family of pattern recognition receptors expressed on many cell types of innate immunity, recognize the pathogen-associated molecular patterns of microbes. The hygiene hypothesis suggests that a reduced microbial exposure in early childhood increases the susceptibility to allergic diseases due to deviation in development of the immune system. TLRs are key roles in the right and healthy direction of adaptive immunity with the induction of T-helper 2 toward Th1 immune responses and regulatory T cells...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28231724/a-rapid-response-to-pembrolizumab-in-a-patient-with-metastatic-melanoma
#20
Juan Bayo Calero, Victoria Aviñó Tarazona
Prognosis for patients with metastatic melanoma stays poor. Recent advances in the field of immuno-oncology increased treatment options for these patients and gave chances for obtaining partial and even complete response, prolonging survival in a subset of patients. Here, we describe a case of a 55-year-old man with multiple melanoma metastases into lungs who showed an extraordinary response to pembrolizumab used as a first-line treatment. The therapy was well tolerated, with no adverse reactions reported.
March 2017: Immunotherapy
journal
journal
42164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"